Dendreon Finds a Buyer

Over the past month, shares of Dendreon have risen 25%, amid talk that a buyout was a possibility. For now, that talk remains just talk; but the company has found a buyer for its New Jersey facility -- Novartis -- which will raise $43M for the company. In this video, Motley Fool health-care analyst David Williamson tells us why the sale was important for Dendreon, how Novartis will be putting its new facility to use, and if the rumor mill's buyout ideas may materialize somewhere down the road.

Dendreon's run over the past four years witnessed sub-$5 share prices skyrocket to 10-bagger status before tumbling all the way back down below $5, as its revolutionary prostate cancer vaccine Provenge became a lightning rod of debate. But where does that leave investors -- other than a bit nauseous from the roller-coaster ride? Our own David Williamson answers this question, and many more, inside our brand new premium research report on Dendreon. Inside, he details every key issue facing the company, and outlines just how Dendreon intends to regain its former glory. The report also comes with a full year of analyst updates, so claim your copy of this exclusive report today by clicking here now.

The article Dendreon Finds a Buyer originally appeared on Fool.com.

Brenton Flynn has no positions in the stocks mentioned above. David Williamson has no positions in the stocks mentioned above. The Motley Fool owns shares of Dendreon and Johnson & Johnson. Motley Fool newsletter services recommend Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Copyright © 1995 - 2012 The Motley Fool, LLC. All rights reserved. The Motley Fool has a disclosure policy.